SK bioscience, the biopharmaceutical arm of South Korea's SK Group, said on Wednesday it has achieved a "final victory" in a ...

South Korean vaccine developer SK bioscience has won a final ruling in a patent dispute with Moderna (Nasdaq: MRNA) over key ...

SEOUL, April 23 (Yonhap) -- SK bioscience Co., the biopharmaceutical arm of South Korea's SK Group, said Wednesday it has ...

Vaccine stocks are down after the health agency's top immunization official announced the move Monday, citing Secretary Kennedy's 'misinformation and lies.' ...

Considering that PD-1/L1 are some of the most lucrative drug treatments across the industry, this could be a major coup for any mRNA developer that manages to successfully co-develop such a treatment.

Five researchers have been jointly awarded one of this year's Breakthrough Prizes in Life Sciences for their contributions to the development of Ozempic-style drugs.

Beyond vaccines, pharma is looking to develop mRNA vaccines to treat diseases requiring protein expression, such as cancer. Cancer has proved to be a graveyard for vaccine developers, however ...

Kennedy Jr. has alluded to in the past, this could have major repercussions for vaccine developers. Companies like Moderna (NASDAQ:MRNA) spend years playing by the rules of the FDA. If authorities ...

The company recently secured approval for olezarsen in FCS, and looks odds on for a follow-up approval in SHTG. Click here to ...